This Article Full Text Full Text (PDF) Online Data Supplement Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Martin, R. J. Articles by Sorkness, C. A. Search for Related Content PubMed PubMed Citation Articles by Martin, R. J. Articles by Sorkness, C. A.

Systemic Effect Comparisons of Six Inhaled Corticosteroid Preparations

National Jewish Medical and Research Center, Denver, Colorado; The University of California at San Francisco, California; Penn State Medical Center, Hershey, Pennsylvania; The University of Wisconsin, Madison, Wisconsin; Thomas Jefferson University, Philadelphia, Pennsylvania; Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts; Harlem Hospital Center and Columbia University, New York; and McMaster University, Hamilton, Ontario, Canada

Correspondence and requests for reprints should be addressed to Richard J. Martin, M.D., National Jewish Medical and Research Center, 1400 Jackson Street, Denver, CO 80206. E-mail: martinr{at}njc.org

The goal of this study was to establish a reliable method to evaluate systemic bioavailability and to determine equisystemic effects (microgram dose producing equal systemic cortisol suppression) of inhaled corticosteroids (ICS). Steroid naive asthma subjects (n = 156) were enrolled at six centers. A 1-week doubling dose design was used for each of six ICS and matched placebos for a total of four doses. Systemic effect was evaluated by hourly plasma cortisol concentrations (8 P.M. to 8 A.M.), 12- and 24-hour urine cortisol concentrations, and a morning blood osteocalcin. The area under the concentration–time curve for hourly cortisol concentrations was the best outcome variable to assess systemic effect. For the six ICS and matching placebos (beclomethasone-chlorofluorocarbon [CFC], budesonide dry powder inhaler [DPI], fluticasone DPI, fluticasone-CFC metered dose inhaler [MDI], flunisolide-CFC, and triamcinolone-CFC), only the placebo group and fluticasone DPI did not demonstrate a significant dose–response effect. Thus microgram comparison of all ICS could only be performed at a 10% cortisol suppression: flunisolide-CFC - 936; triamcinolone-CFC - 787; beclomethasone-CFC - 548; fluticasone DPI - 445; budesonide DPI - 268; fluticasone-CFC MDI - 111. This study represents the first step in evaluation of ICS efficacy based on equisystemic (cortisol suppression) effects of a given ICS, rather than doses judged arbitrarily to be comparable on a microgram basis.

Key Words: inhaled corticosteroids • systemic effects • cortisol suppression

This article has been cited by other articles:

				S. Suissa, R. McGhan, D. Niewoehner, and B. Make Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease Proceedings of the ATS, October 1, 2007; 4(7): 535 - 542. [Abstract] [Full Text] [PDF]

				S. C. Lazarus, V. M. Chinchilli, N. J. Rollings, H. A. Boushey, R. Cherniack, T. J. Craig, A. Deykin, E. DiMango, J. E. Fish, J. G. Ford, et al. Smoking Affects Response to Inhaled Corticosteroids or Leukotriene Receptor Antagonists in Asthma Am. J. Respir. Crit. Care Med., April 15, 2007; 175(8): 783 - 790. [Abstract] [Full Text] [PDF]

				H. Derendorf, R. Nave, A. Drollmann, F. Cerasoli, and W. Wurst Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma. Eur. Respir. J., November 1, 2006; 28(5): 1042 - 1050. [Abstract] [Full Text] [PDF]

				M. Masoli, M. Weatherall, S. Holt, P. Shirtcliffe, and R. Beasley Inhaled fluticasone propionate and adrenal effects in adult asthma: systematic review and meta-analysis Eur. Respir. J., November 1, 2006; 28(5): 960 - 967. [Abstract] [Full Text] [PDF]

				J Paton, E Jardine, E McNeill, S Beaton, P Galloway, D Young, and M Donaldson Adrenal responses to low dose synthetic ACTH (Synacthen) in children receiving high dose inhaled fluticasone Arch. Dis. Child., October 1, 2006; 91(10): 808 - 813. [Abstract] [Full Text] [PDF]

				D. Kohler, P. Haidl, D. Dellweg, L. Bont, J. L.L. Kimpen, M. J.J. Ermers, E. Baraldi, M. Filippone, T. Guilbert, F. D. Martinez, et al. Inhaled corticosteroids and children. N. Engl. J. Med., August 10, 2006; 355(6): 624 - 624. [Full Text] [PDF]

				R. S. Irwin and N. D. Richardson Side Effects With Inhaled Corticosteroids: The Physician's Perception Chest, July 1, 2006; 130(1_suppl): 41S - 53S. [Abstract] [Full Text] [PDF]

				S. Szefler, S. Rohatagi, J. Williams, M. Lloyd, S. Kundu, and D. Banerji Ciclesonide, a Novel Inhaled Steroid, Does Not Affect Hypothalamic-Pituitary-Adrenal Axis Function in Patients With Moderate-to-Severe Persistent Asthma Chest, September 1, 2005; 128(3): 1104 - 1114. [Abstract] [Full Text] [PDF]

				G. P. Chrousos, L. Ghaly, A. Shedden, D. G. Iezzoni, and A. G. Harris Effects of Mometasone Furoate Dry Powder Inhaler and Beclomethasone Dipropionate Hydrofluoroalkane and Chlorofluorocarbon on the Hypothalamic-Pituitary-Adrenal Axis in Asthmatic Subjects Chest, July 1, 2005; 128(1): 70 - 77. [Abstract] [Full Text] [PDF]

				F. de Vries, T. P. van Staa, M. S. G. M. Bracke, C. Cooper, H. G. M. Leufkens, and J-W. J. Lammers Severity of obstructive airway disease and risk of osteoporotic fracture Eur. Respir. J., May 1, 2005; 25(5): 879 - 884. [Abstract] [Full Text] [PDF]

				J. F. Donohue and J. A. Ohar Effects of Corticosteroids on Lung Function in Asthma and Chronic Obstructive Pulmonary Disease Proceedings of the ATS, November 1, 2004; 1(3): 152 - 160. [Abstract] [Full Text] [PDF]

				D. P. Tashkin, H. E. Murray, M. Skeans, R. P. Murray, and for the Lung Health Study Research Group Skin Manifestations of Inhaled Corticosteroids in COPD Patients: Results From Lung Health Study II Chest, October 1, 2004; 126(4): 1123 - 1133. [Abstract] [Full Text] [PDF]

				S. Rohatagi, S. Appajosyula, H. Derendorf, S. Szefler, R. Nave, K. Zech, and D. Banerji Risk-Benefit Value of Inhaled Glucocorticoids: A Pharmacokinetic/Pharmacodynamic Perspective J. Clin. Pharmacol., January 1, 2004; 44(1): 37 - 47. [Abstract] [Full Text] [PDF]

				L. Agertoft and S. Pedersen Lung Deposition and Systemic Availability of Fluticasone Diskus and Budesonide Turbuhaler in Children Am. J. Respir. Crit. Care Med., October 1, 2003; 168(7): 779 - 782. [Abstract] [Full Text] [PDF]

				E.S. Mendes, A. Pereira, I. Danta, R.C. Duncan, and A. Wanner Comparative bronchial vasoconstrictive efficacy of inhaled glucocorticosteroids Eur. Respir. J., June 1, 2003; 21(6): 989 - 993. [Abstract] [Full Text] [PDF]

				G R G Todd Adrenal crisis due to inhaled steroids is underestimated Arch. Dis. Child., June 1, 2003; 88(6): 554 - 555. [Full Text]

				T. W. Harrison, A. E. Tattersfield, R. J. Martin, and S. J. Szefler Systemic effects of inhaled corticosteroids Am. J. Respir. Crit. Care Med., April 1, 2003; 167(7): 1037 - 1038. [Full Text]

				S. Rohatagi, V. Arya, K. Zech, R. Nave, G. Hochhaus, B. K. Jensen, and J. S. Barrett Population Pharmacokinetics and Pharmacodynamics of Ciclesonide J. Clin. Pharmacol., April 1, 2003; 43(4): 365 - 378. [Abstract] [Full Text] [PDF]

				T W Harrison and A E Tattersfield Plasma concentrations of fluticasone propionate and budesonide following inhalation from dry powder inhalers by healthy and asthmatic subjects Thorax, March 1, 2003; 58(3): 258 - 260. [Abstract] [Full Text] [PDF]

				S. J. Szefler Pediatric Asthma: An Approach to Pharmacogenetics Analysis Chest, March 1, 2003; 123(2007): 434S - 438S. [Full Text] [PDF]

				M. J. Tobin Asthma, Airway Biology, and Nasal Disorders in AJRCCM 2002 Am. J. Respir. Crit. Care Med., February 1, 2003; 167(3): 319 - 332. [Full Text] [PDF]